Neoadjuvant Therapy of Cervical Carcinoma with the Angiogenesis Inhibitor Bevacizumab: a Single-Centre Analysis
- Weitere Titel
-
Neoadjuvante Therapie des Zervixkarzinoms mit dem Angiogeneseinhibitor Bevacizumab: eine monozentrische Auswertung
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Neoadjuvant Therapy of Cervical Carcinoma with the Angiogenesis Inhibitor Bevacizumab: a Single-Centre Analysis ; volume:78 ; number:08 ; year:2018 ; pages:768-774
Geburtshilfe und Frauenheilkunde ; 78, Heft 08 (2018), 768-774
- Beteiligte Personen und Organisationen
-
Junker, Philip
Puppe, Julian
Thangarajah, Fabinshy
Domröse, Christian
Cepic, Angela
Morgenstern, Bernd
Ratiu, Dominik
Hellmich, Martin
Mallmann, Peter
Wirtz, Marina
- DOI
-
10.1055/a-0641-5588
- URN
-
urn:nbn:de:101:1-2019022307145405541420
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Junker, Philip
- Puppe, Julian
- Thangarajah, Fabinshy
- Domröse, Christian
- Cepic, Angela
- Morgenstern, Bernd
- Ratiu, Dominik
- Hellmich, Martin
- Mallmann, Peter
- Wirtz, Marina
Ähnliche Objekte (12)
Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903)
ADAR1 overexpression is associated with cervical cancer progression and angiogenesis
Decreased angiogenesis as a possible pathomechanism in cervical degenerative myelopathy
Decreased angiogenesis as a possible pathomechanism in cervical degenerative myelopathy
Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival
Co-delivery of Liposomal Ketoconazole and Bevacizumab for Synergistical Inhibition of Angiogenesis Against Endometrial Cancer
Bevacizumab for the treatment of surgically unresectable cervical cord hemangioblastoma: a case report
Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity
An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients
Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903)
ADAR1 overexpression is associated with cervical cancer progression and angiogenesis
Decreased angiogenesis as a possible pathomechanism in cervical degenerative myelopathy
Decreased angiogenesis as a possible pathomechanism in cervical degenerative myelopathy
Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival
Co-delivery of Liposomal Ketoconazole and Bevacizumab for Synergistical Inhibition of Angiogenesis Against Endometrial Cancer
Bevacizumab for the treatment of surgically unresectable cervical cord hemangioblastoma: a case report
Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity
An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients
Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903)
ADAR1 overexpression is associated with cervical cancer progression and angiogenesis
Decreased angiogenesis as a possible pathomechanism in cervical degenerative myelopathy
Decreased angiogenesis as a possible pathomechanism in cervical degenerative myelopathy
Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival
Co-delivery of Liposomal Ketoconazole and Bevacizumab for Synergistical Inhibition of Angiogenesis Against Endometrial Cancer
Bevacizumab for the treatment of surgically unresectable cervical cord hemangioblastoma: a case report
Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity
An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab